Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Karen Hambardzumyan, Rebecca Bolce, Saedis Saevarsdottir, Scott E Cruickshank, Eric H Sasso, David Chernoff, Kristina Forslind, Ingemar Petersson, Pierre Geborek, Ronald F van Vollenhoven

Research output: Contribution to journalArticlepeer-review

Abstract

Prediction of radiographic progression (RP) in early rheumatoid arthritis (eRA) would be very useful for optimal choice among available therapies. We evaluated a multi-biomarker disease activity (MBDA) score, based on 12 serum biomarkers as a baseline predictor for 1-year RP in eRA.
Original languageEnglish
Pages (from-to)1102-1109
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number6
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Rheumatology and Autoimmunity

Fingerprint

Dive into the research topics of 'Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.'. Together they form a unique fingerprint.

Cite this